Omega-3, Gum Disease, and Diabetes: What Chemerin Can Tell Us

Omega-3 supplements may lower chemerin, an inflammatory adipokine, when added to gum treatment for people with type 2 diabetes and periodontitis. That is an interesting signal, not evidence that fish oil prevents heart attacks or that periodontal therapy can replace diabetes care. The only direct trial was small, used chemerin as a secondary outcome, and followed participants for six months.

The broader idea deserves attention because periodontitis and type 2 diabetes can reinforce each other. High blood glucose can worsen periodontal tissue damage, while periodontal inflammation can add to the inflammatory and oxidative burden of diabetes. Standard treatment—scaling and root planing (SRP), which removes plaque and calculus below the gumline—helps. A 2024 meta-analysis of randomized trials found that periodontal therapy alone reduced systemic inflammatory and oxidative-stress biomarkers in people with diabetes. The open question is whether any add-on treatment produces benefits beyond that baseline improvement.

The omega-3 result is intriguing, but narrow

A 2025 randomized clinical trial by Ghalwash et al. enrolled 30 people with type 2 diabetes and periodontitis at one center in Egypt. Fifteen received SRP plus 1,000 mg per day of omega-3 fatty acids for six months; 15 received SRP alone. The primary endpoint was clinical attachment level, a measure of the support around a tooth. Chemerin in gingival crevicular fluid and serum was a secondary endpoint.

The abstract reports that the omega-3 group had better periodontal measures—pocket depth, clinical attachment level, plaque index, and gingival index—along with lower HbA1c and lower local and circulating chemerin than the SRP-only group at six months. Those findings fit a plausible biological story: omega-3 fatty acids can affect triglycerides and inflammatory signaling in type 2 diabetes. A 2022 systematic review and meta-analysis found effects on cardiovascular risk biomarkers, including triglycerides and glycemic measures, in people with type 2 diabetes.

But the chemerin result cannot carry more weight than the study allows. The trial had 15 participants per group and was powered for clinical attachment level, not chemerin. The available publication information does not permit independent confirmation of chemerin effect sizes, p-values, or confidence intervals. Without those numbers, readers cannot judge the precision or practical size of the reported difference.

Chemerin also remains a surrogate marker. A 2022 case-control study by Mir et al. linked chemerin dysregulation with type 2 diabetes, but its cross-sectional design cannot establish whether chemerin contributes to disease, results from disease, or merely travels alongside it. The available evidence does not establish chemerin as an independent predictor of future cardiovascular events in people with type 2 diabetes. Lower chemerin therefore does not yet mean lower cardiovascular risk.

Why SRP makes adjunct trials hard to interpret

Every participant in the omega-3 trial received SRP. That was appropriate care, but it complicates attribution. SRP itself reduces the bacterial burden in periodontal pockets and, according to the 2024 meta-analysis, can improve systemic inflammatory and oxidative-stress markers in diabetes. An improvement in the omega-3 arm may reflect the shared periodontal treatment, the supplement, differences between groups, or some combination of all three.

The comparison with SRP alone does test whether the package performed better than SRP alone. It does not isolate every pathway behind the difference. A factorial trial—one designed to separate SRP and omega-3 effects—would answer that question more cleanly. It would also need chemerin as a prespecified primary endpoint and enough participants to estimate the effect with useful precision.

Ozone points to the same biological target

The omega-3 trial is not the only effort to address the oxidative-inflammatory burden that can persist in diabetes-associated periodontitis. In a 2023 randomized clinical trial, Rapone et al. tested gaseous ozone as an adjunct to non-surgical periodontal treatment in patients with type 2 diabetes and moderate or severe periodontitis. The trial reported improved oxidizing status with periodontal treatment plus ozone.

Ozone has antimicrobial properties and may influence antioxidant defenses and reactive-oxygen-species signaling. Those mechanisms differ from omega-3 signaling and from mechanical plaque removal, which makes the directional agreement scientifically interesting. Still, this is early evidence, not a reason to seek ozone treatment as a cardiovascular intervention. The study was a single early-stage trial in a specific population, and its design shares the same central challenge: both groups receive periodontal treatment, so the size of ozone's independent contribution remains uncertain.

Polyphenols have a wider, less direct evidence base

Polyphenols—plant compounds found in foods and supplements such as ginger, curcumin, and resveratrol—offer a third route into the same hypothesis. A 2024 systematic review by Rogalnikovaite et al. searched eight databases and identified 10 studies of systemic polyphenols for periodontitis associated with diabetes, spanning diabetic animal models and human studies. Three clinical studies reported significant reductions in probing depth and clinical attachment loss. The review concluded that polyphenols may enhance combined treatment, while emphasizing the limited and uneven human evidence.

The mechanistic case is stronger than the direct clinical case. A systematic review of human intervention trials found that dietary phytochemicals can activate Nrf2, a regulator of antioxidant-response genes. Separately, a 2025 systematic review and meta-analysis reported that polyphenol-rich interventions reduced inflammatory or oxidative-stress markers in adults who were overweight or obese. Those populations overlap metabolically with type 2 diabetes, but they are not interchangeable with people who have both diabetes and periodontitis. A plausible mechanism does not fill the gap left by scarce direct trials.

What the convergence does—and does not—show

Omega-3s, ozone, and polyphenols act through different proposed mechanisms, yet each has produced a signal related to inflammation or oxidative stress in the diabetes-periodontitis setting or in closely related metabolic populations. That convergence supports a reasonable research hypothesis: reducing periodontal disease may help systemic metabolic biology, and some adjuncts may add to that benefit.

It does not prove that all three treatments work equally well, that they lower cardiovascular events, or that a reduction in a biomarker predicts a meaningful health outcome. The strongest established point remains simpler: treating periodontitis in people with type 2 diabetes can improve inflammatory and oxidative-stress markers. The adjunct evidence is less mature.

For patients, the practical priority is evidence-based periodontal care and standard diabetes treatment. Omega-3, ozone, and polyphenol strategies belong in the "watch closely" category until larger, replicated trials show which adjuncts improve outcomes that patients can actually feel or measure beyond a laboratory marker.

The next useful studies will compare adjuncts against carefully matched SRP-only groups, enroll diverse populations, report confidence intervals, and follow participants long enough to assess durable glycemic outcomes. For omega-3 specifically, they should prespecify chemerin and test whether changing it predicts anything beyond a lower chemerin value.